Verification evidence is still being completed.
PDF / print export
Celon Pharma S.A.
Łomianki, Poland
- Verified lead
- Dr. Maciej Wieczorek
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO and President of the Management Board
- 2026 technical specialization
- R&D in Oncology and Neurology
- Review cycle
- May 2026
- Full address
- Ogrodowa 2 A, 05-092 Łomianki / Kiełpin, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Celon Pharma company profile confirming Dr. Maciej Wieczorek as CEO and President of the Management Board.
- Editorial note
- Integrated R&D and manufacturing footprint spanning oncology, neurology, and inhalation programs with scale-up capability in Poland.
R&D in Oncology and Neurology
Integrated biopharmaceutical manufacturing platform
Integrated R&D and manufacturing footprint spanning oncology, neurology, and inhalation programs with scale-up capability in Poland.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Łomianki, Poland
Celon Pharma S.A.
R&D in Oncology and Neurology · Integrated therapeutic R&D and manufacturing
Verified 14 Mar 2026 · 2 sources
Commercial
Integrated R&D and manufacturing footprint spanning oncology, neurology, and inhalation programs with scale-up capability in Poland.
Contact & location
- Website
- celonpharma.com
- Company page
- Lead
- Dr. Maciej Wieczorek (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 14 Mar 2026 (4mo ago)
- Scale
- Integrated therapeutic R&D and manufacturing
- Capabilities
- Oncology Research · Neurology Programs · Therapeutic Discovery
- Founded
- 2002
- Headcount
- 201-500
R&D in Oncology and Neurology
Integrated R&D and manufacturing footprint spanning oncology, neurology, and inhalation programs with scale-up capability in Poland.
Editorial note
Integrated therapeutic R&D and manufacturing platform under direct executive control.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Verification details
Clinical profileSTATUS: VERIFIED MARCH 2026
Dr. Maciej Wieczorek
CEO and President of the Management Board
Full addressOgrodowa 2 A, 05-092 Łomianki / Kiełpin, Poland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Celon Pharma privacy page listing the registered office at Ogrodowa 2 A in Kiełpin / Łomianki.
Open sourceIntegrated therapeutic R&D and manufacturing
Łomianki, Poland. R&D in Oncology and Neurology. Review completed on 14 Mar 2026.
Polish and EU pharmaceutical oversight
Integrated biopharmaceutical manufacturing platform
Capabilities
Oncology Research
Neurology Programs
Therapeutic Discovery
Sources
The official sources used to verify this profile.
Infrastructure
Equipment detail not disclosed in the current record.
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
Frequently asked questions
- Where is Celon Pharma S.A. located?
- Celon Pharma S.A. operates from Ogrodowa 2 A, 05-092 Łomianki / Kiełpin, Poland, Łomianki, Poland.
- Who runs Celon Pharma S.A.?
- Celon Pharma S.A. is led by Dr. Maciej Wieczorek, CEO and President of the Management Board. Verified 14 Mar 2026.
- What does Celon Pharma S.A. do?
- Integrated R&D and manufacturing footprint spanning oncology, neurology, and inhalation programs with scale-up capability in Poland. Core capabilities: Oncology Research, Neurology Programs, Therapeutic Discovery.
Editorial context
Related technical briefs
Briefs that name Łomianki as a covered market or city.